

# Real-World Experience With TriNav LV


The TriNav® LV Infusion System is here! Designed for vessels 3.5 mm to 5.0 mm, TriNav LV employs the same Pressure-Enabled Drug Delivery™ (PEDD™) approach that has been shown to increase the T:N ratio and improve outcomes for complex patients. 1,2 Interventional Radiologists are already sharing their real-world experiences using the latest TriNav innovation.

Dr Zachary Berman from the University of California, San Diego used TriNav LV to deliver resin Y90 TARE to treat metastatic leiomyosarcoma. Side-by-side imaging from the case shows how TriNav LV significantly improved the tumor targeting compared with a traditional microcatheter, while also decreasing delivery to the normal liver - effectively increasing the T:N ratio. This was confirmed on dosimetry.


You can read the full case study and see all the imaging here

## **Target Tumors**

**Traditional Microcatheter MAA SPECT** 




**TriNav LV Y90 SPECT** 




# **Background Liver**

**Traditional Microcatheter MAA SPECT** 



TriNav LV **Y90 SPECT** 



Visit our website to learn more about TriNav LV and how it may benefit your most complex patients.

Request an appointment with a sales representative

#### **Indications For Use** The TriNav and TriNav LV Infusion Systems are intended for use in angiographic procedures. They deliver

radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.<sup>3,4</sup> Contraindications

### The TriNav and TriNav LV Infusion Systems are not indicated for use in the vasculature of the central nervous

system (including the neurovasculature) or central circulatory system (including the coronary vasculature).<sup>3,4</sup>

# **Rx Only**

For the safe and proper use of the TriNav and TriNav LV Infusion Systems, refer to their individual Instructions for Use.

### References

- 1. d'Abadie P, Walrand S, Goffette P, et al. Antireflux catheter improves tumor targeting in liver radioembolization with resin microspheres. Diagn Interv Radiol. 2021;27(6):768-773.
- 2. Cook K, Gupta D, Liu Y, et al. Real-world evidence of Pressure-Enabled Drug Delivery for trans-arterial chemoembolization and radioembolization among patients with hepatocellular carcinoma and liver metastases. Curr Med Res Opin. 2024;40(4):591-598.
- 3. TriSalusTM TriNav® Infusion System Instructions for Use.
- 4. TriSalusTM TriNav® LV Infusion System Instructions for Use.



© 2024 TriSalus™ Life Sciences. All rights reserved. MDG-0308 V1.0